Comparing the current results to its competitors, Terns Pharmaceuticals Inc reported Revenue decrease in the 4 quarter 2025 year on year by 0 %, despite the revenue increase by the most of its competitors of 13.23 %, recorded in the same quarter.
Terns Pharmaceuticals Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 99.31 %
Terns Pharmaceuticals Inc 's Comment on Competition and Industry Peers
The company operates in the drug discovery and development sector, facing significant competition in a rapidly evolving technological and scientific environment. Its product candidates, if approved, will encounter competition that may limit market penetration. Several competitors, including Merck Sharp & Dohme LLC and Thailand Merger Sub, Inc., possess substantially greater resources, which could impact the company's competitive position. The company also faces risks related to regulatory approval processes, particularly for indications lacking clearly defined regulatory pathways, potentially affecting the timing and costs of clinical development. Additionally, the company is subject to risks associated with a merger agreement involving Merck Sharp & Dohme LLC and Thailand Merger Sub, Inc., including uncertainties regarding the timing, completion, and regulatory approvals required for the merger.
June 21, 2024
Obesity is a global health crisis that affects millions of people worldwide, leading to a wide range of health complications, including diabetes, cardiovascular diseases, and even certain types of cancer. Developing effective strategies to combat obesity is of utmost importance, and these new findings from Terns Pharmaceuticals provide a glimmer of hope and renewed optimism.The GLP-1 receptor agonist alone has already proven to be an effective tool in managing body weight, appetite, and glucose regulation. However, TERN-501 takes it a step further by addressing a crucial aspect of weight loss energy expenditure. By normalizing energy expenditure, TERN-501 amplifies the impact of the GLP-1 receptor agonist,...
April 29, 2024
Terns Pharmaceuticals, a leading biopharmaceutical company, recently released data from an ongoing Phase 1 pharmacokinetic study of their novel allosteric BCR-ABL inhibitor TERN-701. The study focused on adult healthy volunteers and highlighted the potential for competitive differentiation in the treatment of certain types of cancers. One key aspect that sets TERN-701 apart from other drugs in its class is the ability to dose it without regard to food, a feature that can greatly enhance patient convenience and treatment adherence.The Phase 1 study aimed to assess the safety and pharmacokinetics of TERN-701 in healthy adult participants. The results showed promising outcomes, demonstrating that the drug was w...
March 11, 2024
Terns Pharmaceuticals, a prominent clinical-stage biopharmaceutical company dedicated to combatting severe diseases, including oncology and obesity, has successfully obtained Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for their innovative drug, TERN-701. This significant milestone marks a major breakthrough in the treatment of chronic myeloid leukemia (CML), a relentless form of blood cancer that affects thousands of patients worldwide.TERN-701, an internally discovered allosteric BCR-ABL tyrosine kinase inhibitor (TKI), has shown immense potential in early clinical trials. Currently in Phase 1 development, the drug offers an exciting new approach to combating CML by targeting s...
Publicly Traded Peers of Terns Pharmaceuticals Inc
Supernus Pharmaceuticals inc Share Performance
-5.96%
30 Days
Supernus Pharmaceuticals inc
Profile
Supernus Pharmaceuticals Inc operates under a unique business model focused on the development and commercialization of innovative treatments for central nervous system (CNS) diseases. The company combines in-house expertise with strategic partnerships to efficiently advance and bring their products to market. By prioritizing CNS disorders and utilizing a collaborative approach, Supernus Pharmaceuticals strives to address unmet medical needs and improve the lives of patients.
Ligand Pharmaceuticals Inc operates on a business model focused on discovering and acquiring new drugs and technologies to license them to pharmaceutical companies. They generate revenue through licensing fees, milestone payments, and royalties from the sales of their partnered products. Their approach allows them to leverage their expertise and resources while minimizing risk, ultimately leading to long-term value creation for their shareholders.
Durect Corp operates as a specialty pharmaceutical company that develops and commercializes innovative products for the treatment of chronic diseases. Their business model revolves around the research, development, and commercialization of their proprietary drug delivery technologies and therapeutics to address unmet medical needs.
Adagene Inc is a biotechnology company that develops novel antibody therapeutics for cancer treatment by leveraging its proprietary Dynamic Precision Library platform. Their business model involves partnering with pharmaceutical companies for the development and commercialization of their products.
Sources:
Terns Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Terns Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
